Pcsk9
-
{
- All
- News
-
Bad Cholesterol Reduction: Single Gene Therapy Dose Shows 62% Drop
A one-time gene therapy for treating hypercholesterolaemia could lower up to 62 per cent 'bad' cholesterol in the blood, with reductions sustaining over time, according to results of a clinical trial published in The New England Journal of Medicine.
-
New One-Shot Gene Editing Therapy May Reduce Bad Cholesterol By 62%
A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62% after a single infusion in an early trial, raising hopes for a long-lasting treatment to reduce heart attack risk
-
New DNA-Based Therapy Can Help Lower 'Bad Cholesterol' Without Statins, Finds Study
Researchers used tiny DNA-based molecules to cut levels of LDL (bad) cholesterol by nearly 50% in animal models. This was done without the side effects that are often linked to statins.
-
New Oral Pill Enlicitide Cuts 'Bad' Cholesterol By 60% In Landmark Trial
The new oral pill enlicitide cuts bad cholesterol risk by 60% in a new landmark trial. Here are the mechanisms behind it and why the oral pill could revolutionise cholesterol management.
-
New Experimental Drug Enlicitide May Cut "Bad" Cholesterol By Up To 60%
A new daily oral medication, enlicitide, has shown reductions in LDL cholesterol of up to 60% in a late-stage Phase 3 trial, matching the efficacy of injectable PCSK9 inhibitors.
-
Protein Linked to Heart Attack Identified
A protein that increases levels of LDL (low-density lipoprotein) cholesterol, also referred to as "bad" cholesterol, in the bloodstream is associated with heart attacks, says a study.
-
Bad Cholesterol Reduction: Single Gene Therapy Dose Shows 62% Drop
A one-time gene therapy for treating hypercholesterolaemia could lower up to 62 per cent 'bad' cholesterol in the blood, with reductions sustaining over time, according to results of a clinical trial published in The New England Journal of Medicine.
-
New One-Shot Gene Editing Therapy May Reduce Bad Cholesterol By 62%
A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62% after a single infusion in an early trial, raising hopes for a long-lasting treatment to reduce heart attack risk
-
New DNA-Based Therapy Can Help Lower 'Bad Cholesterol' Without Statins, Finds Study
Researchers used tiny DNA-based molecules to cut levels of LDL (bad) cholesterol by nearly 50% in animal models. This was done without the side effects that are often linked to statins.
-
New Oral Pill Enlicitide Cuts 'Bad' Cholesterol By 60% In Landmark Trial
The new oral pill enlicitide cuts bad cholesterol risk by 60% in a new landmark trial. Here are the mechanisms behind it and why the oral pill could revolutionise cholesterol management.
-
New Experimental Drug Enlicitide May Cut "Bad" Cholesterol By Up To 60%
A new daily oral medication, enlicitide, has shown reductions in LDL cholesterol of up to 60% in a late-stage Phase 3 trial, matching the efficacy of injectable PCSK9 inhibitors.
-
Protein Linked to Heart Attack Identified
A protein that increases levels of LDL (low-density lipoprotein) cholesterol, also referred to as "bad" cholesterol, in the bloodstream is associated with heart attacks, says a study.
